Research statistics

Orexin-A research: publications and trials

What has been published on Orexin-A: PubMed publications, the kind of evidence they report and registered clinical trials. These are counts of research, not a judgment of whether Orexin-A works or is safe. For what it is and what the studies found, see the Orexin-A profile.
Automated weekly refresh · data through November 15, 2026

At a glance

Publications, all years

2,764

Since 1998

Publications in 2026 so far

99

Through November 15, 2026

Human clinical research

15.4%

424 of 2,759 classified

Registered clinical trials

0

ClinicalTrials.gov

Randomized controlled trials

24

Publications reporting an RCT in people

Systematic reviews and meta-analyses

11

Preclinical studies

66.5%

1,655 animal · 170 in vitro · 11 computational

Records that only mention it

4,085

Not counted above

Status in the library: Research only. Groups: Cognitive and neurological peptides. 5 publications are not yet classified by study type.

What to keep in mind

  • The body makes this molecule itself, so much of its literature is physiology rather than research on it as a compound.

Publications by year

Orexin-A publications by year and evidence

1998, Preclinical (animal, in vitro, computational): 5 of 61998, Reviews and meta-analyses: 1 of 61999, Preclinical (animal, in vitro, computational): 41 of 451999, Reviews and meta-analyses: 4 of 452000, Human clinical research: 2 of 522000, Preclinical (animal, in vitro, computational): 41 of 522000, Reviews and meta-analyses: 6 of 522000, Other and not yet classified: 3 of 522001, Human clinical research: 7 of 952001, Preclinical (animal, in vitro, computational): 77 of 952001, Reviews and meta-analyses: 10 of 952001, Other and not yet classified: 1 of 952002, Human clinical research: 18 of 1142002, Preclinical (animal, in vitro, computational): 79 of 1142002, Reviews and meta-analyses: 15 of 1142002, Other and not yet classified: 2 of 1142003, Human clinical research: 18 of 1082003, Preclinical (animal, in vitro, computational): 74 of 1082003, Reviews and meta-analyses: 10 of 1082003, Other and not yet classified: 6 of 1082004, Human clinical research: 11 of 852004, Preclinical (animal, in vitro, computational): 65 of 852004, Reviews and meta-analyses: 8 of 852004, Other and not yet classified: 1 of 852005, Human clinical research: 14 of 1062005, Preclinical (animal, in vitro, computational): 81 of 1062005, Reviews and meta-analyses: 9 of 1062005, Other and not yet classified: 2 of 1062006, Human clinical research: 10 of 862006, Preclinical (animal, in vitro, computational): 63 of 862006, Reviews and meta-analyses: 10 of 862006, Other and not yet classified: 3 of 862007, Human clinical research: 12 of 822007, Preclinical (animal, in vitro, computational): 50 of 822007, Reviews and meta-analyses: 19 of 822007, Other and not yet classified: 1 of 822008, Human clinical research: 11 of 962008, Preclinical (animal, in vitro, computational): 65 of 962008, Reviews and meta-analyses: 17 of 962008, Other and not yet classified: 3 of 962009, Human clinical research: 11 of 1122009, Preclinical (animal, in vitro, computational): 75 of 1122009, Reviews and meta-analyses: 26 of 1122010, Human clinical research: 14 of 1012010, Preclinical (animal, in vitro, computational): 72 of 1012010, Reviews and meta-analyses: 14 of 1012010, Other and not yet classified: 1 of 1012011, Human clinical research: 18 of 982011, Preclinical (animal, in vitro, computational): 66 of 982011, Reviews and meta-analyses: 12 of 982011, Other and not yet classified: 2 of 982012, Human clinical research: 15 of 1152012, Preclinical (animal, in vitro, computational): 64 of 1152012, Reviews and meta-analyses: 34 of 1152012, Other and not yet classified: 2 of 1152013, Human clinical research: 16 of 1062013, Preclinical (animal, in vitro, computational): 69 of 1062013, Reviews and meta-analyses: 21 of 1062014, Human clinical research: 16 of 1282014, Preclinical (animal, in vitro, computational): 87 of 1282014, Reviews and meta-analyses: 21 of 1282014, Other and not yet classified: 4 of 1282015, Human clinical research: 9 of 1032015, Preclinical (animal, in vitro, computational): 86 of 1032015, Reviews and meta-analyses: 7 of 1032015, Other and not yet classified: 1 of 1032016, Human clinical research: 21 of 992016, Preclinical (animal, in vitro, computational): 75 of 992016, Reviews and meta-analyses: 3 of 992017, Human clinical research: 8 of 1032017, Preclinical (animal, in vitro, computational): 72 of 1032017, Reviews and meta-analyses: 21 of 1032017, Other and not yet classified: 2 of 1032018, Human clinical research: 17 of 1322018, Preclinical (animal, in vitro, computational): 89 of 1322018, Reviews and meta-analyses: 25 of 1322018, Other and not yet classified: 1 of 1322019, Human clinical research: 20 of 922019, Preclinical (animal, in vitro, computational): 63 of 922019, Reviews and meta-analyses: 7 of 922019, Other and not yet classified: 2 of 922020, Human clinical research: 26 of 1002020, Preclinical (animal, in vitro, computational): 51 of 1002020, Reviews and meta-analyses: 23 of 1002021, Human clinical research: 13 of 1082021, Preclinical (animal, in vitro, computational): 67 of 1082021, Reviews and meta-analyses: 28 of 1082022, Human clinical research: 31 of 1122022, Preclinical (animal, in vitro, computational): 58 of 1122022, Reviews and meta-analyses: 22 of 1122022, Other and not yet classified: 1 of 1122023, Human clinical research: 11 of 882023, Preclinical (animal, in vitro, computational): 54 of 882023, Reviews and meta-analyses: 21 of 882023, Other and not yet classified: 2 of 882024, Human clinical research: 22 of 962024, Preclinical (animal, in vitro, computational): 57 of 962024, Reviews and meta-analyses: 17 of 962025, Human clinical research: 26 of 972025, Preclinical (animal, in vitro, computational): 47 of 972025, Reviews and meta-analyses: 20 of 972025, Other and not yet classified: 4 of 972026 (to date), Human clinical research: 27 of 992026 (to date), Preclinical (animal, in vitro, computational): 43 of 992026 (to date), Reviews and meta-analyses: 22 of 992026 (to date), Other and not yet classified: 7 of 99Human clinical researchPreclinical (animal, in vitro, computational)Reviews and meta-analysesOther and not yet classified05010015019982004201020162026*
Counted PubMed publications by year of first publication. * 2026 runs to November 15, 2026. A larger bar is more publications, not stronger evidence.
Show the data
YearHuman clinical researchPreclinical (animal, in vitro, computational)Reviews and meta-analysesOther and not yet classifiedTotal
199805106
19990414045
20002416352
200177710195
20021879152114
20031874106108
200411658185
2005148192106
2006106310386
2007125019182
2008116517396
20091175260112
20101472141101
2011186612298
20121564342115
20131669210106
20141687214128
201598671103
201621753099
2017872212103
20181789251132
201920637292
20202651230100
20211367280108
20223158221112
2023115421288
2024225717096
2025264720497
2026 (to date)274322799

Study types

Animal study1,655
Review442
Observational human study317
In vitro study170
Case report48
Editorial, letter or other46
Other clinical trial35
Randomized controlled trial24
Computational study11
Systematic review7
Not yet classified5
Meta-analysis4

Research areas

From MeSH major topics. A paper can be in several areas.

Neurological and mental health2,107
Metabolic health308
Endocrinology286
Cognitive health265
Obesity and weight management243
Cardiovascular169
Gastrointestinal139
Reproductive and sexual health119
Immune system115
Musculoskeletal110
Oncology74
Longevity and aging52

Registered clinical trials

A registration is not a result.

No registered trials.

Human trials and evidence reviews

Meta-analyses, systematic reviews and trials in people, newest first.

  1. Exploring the role of Orexin-A neuropeptide in Parkinson's disease: A systematic review and meta-analysis.

    Clinical neurology and neurosurgery · May 12, 2024 · Meta-analysis · cited 5 times

    PMID 38781804 · DOI 10.1016/j.clineuro.2024.108320 · Reviews and meta-analyses

  2. Orexin-A in Patients With Lewy Body Disease: A Systematic Review and Meta-Analysis.

    Frontiers in endocrinology · November 17, 2021 · Meta-analysis · cited 8 times · open access

    PMID 34867809 · DOI 10.3389/fendo.2021.765701 · Reviews and meta-analyses

  3. Cerebrospinal fluid orexin in Alzheimer's disease: a systematic review and meta-analysis.

    Sleep medicine · July 13, 2021 · Meta-analysis · cited 23 times · open access

    PMID 34364094 · DOI 10.1016/j.sleep.2021.07.007 · Reviews and meta-analyses

  4. Sleep disorders in Prader-Willi syndrome, evidence from animal models and humans.

    Sleep medicine reviews · January 20, 2021 · Meta-analysis · cited 31 times

    PMID 33567377 · DOI 10.1016/j.smrv.2021.101432 · Reviews and meta-analyses

  5. Orexin Signaling, Glymphatic Clearance, and Preclinical Alzheimer's Disease: A Scoping Review and Hypothesis-Generating Conceptual Framework.

    Current Alzheimer research · August 6, 2026 · Systematic review · cited 0 times

    PMID 42634303 · DOI 10.2174/0115672050487100260727051112 · Reviews and meta-analyses

  6. The impacts of trauma and stress on orexin expression and signalling: A systematic review.

    Psychiatry research · May 11, 2026 · Systematic review · cited 0 times · open access

    PMID 42134275 · DOI 10.1016/j.psychres.2026.117222 · Reviews and meta-analyses

  7. Physiological significance of autocrine orexinergic signaling in extra-hypothalamic tissues.

    Physiological reports · April 1, 2026 · Systematic review · cited 6 times · open access

    PMID 42033055 · DOI 10.14814/phy2.70892 · Reviews and meta-analyses

  8. Orexinergic pathway as a potential therapeutic candidate for the modulation of glucose homeostasis.

    Frontiers in physiology · December 8, 2025 · Systematic review · cited 14 times · open access

    PMID 41438219 · DOI 10.3389/fphys.2025.1659753 · Reviews and meta-analyses

  9. Orexin and Sleep Disturbances in Alpha-Synucleinopathies: a Systematic Review.

    Current neurology and neuroscience reports · July 20, 2024 · Systematic review · cited 12 times · open access

    PMID 39031323 · DOI 10.1007/s11910-024-01359-6 · Reviews and meta-analyses

  10. Plasma Orexin-A Levels in Patients With Schizophrenia: A Systematic Review and Meta-Analysis.

    Frontiers in psychiatry · May 25, 2022 · Systematic review · cited 9 times · open access

    PMID 35693955 · DOI 10.3389/fpsyt.2022.879414 · Reviews and meta-analyses

Most cited

By OpenAlex citation count. Citations measure attention, not quality or correctness.

  1. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior.

    Cell · February 1, 1998 · Animal study · cited 5,504 times · open access

    PMID 9491897 · DOI 10.1016/s0092-8674(00)80949-6 · Animal studies

  2. Neurons containing hypocretin (orexin) project to multiple neuronal systems.

    The Journal of neuroscience : the official journal of the Society for Neuroscience · December 1, 1998 · Animal study · cited 3,468 times · open access

    PMID 9822755 · DOI 10.1523/jneurosci.18-23-09996.1998 · Animal studies

  3. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation.

    Cell · August 1, 1999 · Animal study · cited 3,095 times · open access

    PMID 10481909 · DOI 10.1016/s0092-8674(00)81973-x · Animal studies

  4. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains.

    Nature medicine · September 1, 2000 · Case report · cited 2,120 times

    PMID 10973318 · DOI 10.1038/79690 · Human clinical research

  5. Hypocretin (orexin) deficiency in human narcolepsy.

    Lancet (London, England) · January 1, 2000 · Editorial, letter or other · cited 1,779 times · open access

    PMID 10615891 · DOI 10.1016/s0140-6736(99)05582-8 · Commentary and other

Latest publications

  1. Interaction between orexinergic and opioidergic systems in the dentate gyrus on modulation of pain-related behaviors in the tail-flick test as the animal model of acute pain in male rats.

    Physiology & behavior · November 5, 2026 · Animal study · cited 0 times

    PMID 42988292 · DOI 10.1016/j.physbeh.2026.115562 · Animal studies

  2. Feedforward Inhibition Mediated by Preoptic Area Parvalbumin Neurons Contributes to Orexin-Induced Active Arousal from Anesthesia.

    Research (Washington, D.C.) · November 5, 2026 · Animal study · cited 0 times · open access

    PMID 42990727 · DOI 10.34133/research.1474 · Animal studies

  3. Targeted temporal interference stimulation of the lateral hypothalamus improves glymphatic function and neurological outcomes after traumatic brain injury.

    Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · November 3, 2026 · Animal study · cited 0 times

    PMID 42976640 · DOI 10.1016/j.neurot.2026.e01108 · Animal studies

  4. The orexinergic-endocannabinoid interface: mechanistic and therapeutic perspectives in Alzheimer's disease, anxiety, and visceral pain.

    Neuropeptides · October 26, 2026 · Review · cited 0 times

    PMID 42950713 · DOI 10.1016/j.npep.2026.102665 · Reviews and meta-analyses

  5. Dysregulation of Orexin-A and Implications for Renal Function Assessment in Chronic Kidney Disease.

    Annals of African medicine · October 19, 2026 · Observational human study · cited 0 times

    PMID 42893839 · DOI 10.4103/aam.aam_809_26 · Human clinical research

  6. The hypothalamic orexin-medial prefrontal cortex pathway modulates susceptibility to depression in the learned helplessness paradigm in male mice.

    The Journal of neuroscience : the official journal of the Society for Neuroscience · October 15, 2026 · Animal study · cited 0 times · open access

    PMID 42880970 · DOI 10.1523/jneurosci.2121-25.2026 · Animal studies

  7. Interventional Effects and Neurometabolic Regulation of a <i>Panax quinquefolius</i>-Containing Herbal Extract (JYF) in Diazepam Withdrawal Syndrome in Mice.

    Pharmaceuticals (Basel, Switzerland) · October 12, 2026 · Animal study · cited 0 times · open access

    PMID 42943314 · DOI 10.3390/ph19101617 · Animal studies

  8. Orexin deficiency and cardiometabolic risk in narcolepsy: mechanistic pathways and therapeutic implications.

    Function (Oxford, England) · October 9, 2026 · Review · cited 0 times

    PMID 42932914 · DOI 10.1152/function.90001.2026 · Reviews and meta-analyses

  9. Pharmacokinetics and immunomodulatory effects of selective orexin 1 receptor agonist OXA 17-33: PBMC responses, HPA axis activation, and outcomes in the collagen-induced arthritis model.

    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · October 9, 2026 · Animal study · cited 0 times · open access

    PMID 42854451 · DOI 10.1016/j.biopha.2026.119980 · Animal studies

  10. Orexin-A and Periosteal Pressure Sensitivity during acute mental and physical stress: a randomized cross-over study.

    Frontiers in neuroscience · October 7, 2026 · Randomized controlled trial · cited 0 times · open access

    PMID 42909892 · DOI 10.3389/fnins.2026.1923282 · Human clinical research

Browse all 2,764 publications in the dashboard

How this is counted

PubMed records matched by the names below, counted when the peptide is in the title, indexed by MeSH, or confirmed from the abstract. The exact query can be rerun on Europe PMC. Methodology

Search terms: Hypocretin-1; Orexin-A

((TITLE_ABS:"Hypocretin-1" OR CHEM:"Hypocretin-1" OR TITLE_ABS:"Hypocretin1" OR CHEM:"Hypocretin1") OR (TITLE_ABS:"Orexin-A" OR CHEM:"Orexin-A")) AND SRC:MED

Cite this page

Peptide Library. (2026, November 16). Orexin-A research statistics (Version weekly-2026-11-15) [Statistic]. Peptide Library. https://peptidelibrary.app/research/peptides/orexin-a